Download or read book Deciphering Drug Targets for Alzheimer s Disease written by Dileep Kumar and published by Springer Nature. This book was released on 2023-10-02 with total page 388 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book explains the fundamental characteristics and biofunctionality of Alzheimer’s Disease drug targets and provides up-to-date information on the full range of their biomedical applications. An introductory section gives an overview of the recent developments related to drug targets identified and studied related to Alzheimer’s Disease and key developments from preclinical and clinical studies focusing on various molecular targets related to AD and dementia by subject experts all around the globe. Here, individual chapters address the progress and perspectives in human and non-human research, role of various biomarkers as an overview, advanced gene therapy, and novel compounds for therapeutic targets for Alzheimer’s disease. The book will be essential reading for graduate students, scientists, and engineers in any of the biomedical research fields in which efforts are being made to utilize novel drug targets and develop effective strategies for new drug targeting and delivery in Alzheimer’s disease treatment.
Download or read book Deciphering Drug Targets for Alzheimer s Disease written by Dileep Kumar and published by Springer. This book was released on 2024-09-02 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book explains the fundamental characteristics and biofunctionality of Alzheimer's Disease drug targets and provides up-to-date information on the full range of their biomedical applications. An introductory section gives an overview of the recent developments related to drug targets identified and studied related to Alzheimer's Disease and key developments from preclinical and clinical studies focusing on various molecular targets related to AD and dementia by subject experts all around the globe. Here, individual chapters address the progress and perspectives in human and non-human research, role of various biomarkers as an overview, advanced gene therapy, and novel compounds for therapeutic targets for Alzheimer's disease. The book will be essential reading for graduate students, scientists, and engineers in any of the biomedical research fields in which efforts are being made to utilize novel drug targets and develop effective strategies for new drug targeting and delivery in Alzheimer's disease treatment.
Download or read book Drug Design and Discovery in Alzheimer s Disease written by Atta-ur Rahman and published by Elsevier. This book was released on 2015-06-27 with total page 785 pages. Available in PDF, EPUB and Kindle. Book excerpt: Drug Design and Discovery in Alzheimer's Disease includes expert reviews of recent developments in Alzheimer's disease (AD) and neurodegenerative disease research. Originally published by Bentham as Frontiers in Drug Design and Discovery, Volume 6and now distributed by Elsevier, this compilation of the sixteen articles, written by leading global researchers, focuses on key developments in the understanding of the disease at molecular levels, identification and validation of molecular targets, as well as innovative approaches towards drug discovery, development, and delivery. Beginning with an overview of AD pharmacotherapy and existing blockbuster drugs, the reviews cover the potential of both natural and synthetic small molecules; the role of cholinesterases in the on-set and progression of AD and their inhibition; the role of beta-site APP clearing enzyme-1 (BACE-1) in the production of ß-amyloid proteins, one of the key reasons of the progression of AD; and other targets identified for AD drug discovery. - Edited and written by leading experts in Alzheimer's disease (AD) and other neurodegenerative disease drug development - Describes existing drugs for AD and current molecular understanding of the condition - Reviews recent advances in the field, including coverage of cholinesterases, BACE-1, and other drug development targets
Download or read book Alzheimer s Disease Research Guide written by Takaomi C. Saido and published by Elsevier. This book was released on 2024-07-25 with total page 284 pages. Available in PDF, EPUB and Kindle. Book excerpt: Alzheimer's Disease Research Guide: Animal Models for Understanding Mechanisms and Medications provides researchers with a comprehensive guide, detailing every aspect of Alzheimer's Disease research, including chapters on neuroinflammation, immunotherapy, biomarkers, and animal modeling. This book begins with historical perspectives of both pathological chronology and pathological biochemistry in relation to Alzheimer's disease. Other chapters review Amyloidogenic AB and Non-Amyloidogenic tau and Metabolism of AB major components to the research and understanding of Alzheimer's research. The book concludes with specific treatment chapters including how to develop safe, effective, and inexpensive medications and the application of genome editing to the treatment of Familial Alzheimer's Disease.Written by world renowned expert in Alzheimer's research, this book is a valuable resource for all researchers. - Reviews why familial Alzheimer's disease is vital to understanding sporadic Alzheimer's disease - Describes the latest "game changer" animal models of Alzheimer's disease and frontotemporal dementia in detail - Explains how various Alzheimer's disease medications have failed clinical trials - Discusses pros and cons of therapeutic antibodies, lecanemab and donanemab, that were recently found to be effective in recent clinical trials - Details the application of genome editing as a treatment for familial Alzheimer's disease - Proposes publishing "Journal of Negative Data" for the days of generative AI-assisted publication, AI being unable to distinguish between reproducible and unreproducible data, particularly important in Alzheimer's research
Download or read book Alzheimer s Disease Drug Development written by Jeffrey Cummings and published by Cambridge University Press. This book was released on 2022-03-31 with total page 575 pages. Available in PDF, EPUB and Kindle. Book excerpt: Provides a definitive overview of the complex ecosystem facilitating Alzheimer's Disease drug research and development. Demonstrates a drug's journey from in the lab, clinical trial testing, regulatory review, and marketing by pharmaceutical companies. Details the use of artificial intelligence, clinical trial management, and financing models.
Download or read book Neuroprotection in Alzheimer s Disease written by Illana Gozes and published by Academic Press. This book was released on 2016-12-30 with total page 344 pages. Available in PDF, EPUB and Kindle. Book excerpt: Neuroprotection in Alzheimer’s Disease offers a translational point-of-view from both basic and clinical standpoints, putting it on the cusp for further clinical development with its emphasis on nerve cell protection, including the accumulation of knowledge from failed clinical trials and new advances in disease management. This book brings together the latest findings, both basic, and clinical, under the same cover, making it easy for the reader to obtain a complete overview of the state-of-the-field and beyond. Alzheimer's disease is the most common form of dementia, accounting for 60 to 80 percent of dementia cases. It is a progressive brain disease that slowly destroys memory, thinking skills, and eventually, even the ability to carry out the simplest tasks. It is characterized by death of synapses coupled to death nerve cells and brain degeneration which is manifested by loss of cognitive abilities. Understanding neuroprotection in Alzheimer’s disease will pave the path to better disease management and novel therapeutics. Comprehensive reference detailing neuroprotection in Alzheimer’s Disease, with details on nerve cell protection and new advances in disease management Combines the knowledge and points-of-view of both medical doctors and basic scientists, putting the subject at the forefront for further clinical development Edited by one of the leading researchers in Alzheimer’s Disease
Download or read book Methods of Behavior Analysis in Neuroscience written by Jerry J. Buccafusco and published by CRC Press. This book was released on 2000-08-29 with total page 341 pages. Available in PDF, EPUB and Kindle. Book excerpt: Using the most well-studied behavioral analyses of animal subjects to promote a better understanding of the effects of disease and the effects of new therapeutic treatments on human cognition, Methods of Behavior Analysis in Neuroscience provides a reference manual for molecular and cellular research scientists in both academia and the pharmaceutic
Download or read book Improving and Accelerating Therapeutic Development for Nervous System Disorders written by Institute of Medicine and published by National Academies Press. This book was released on 2014-02-06 with total page 107 pages. Available in PDF, EPUB and Kindle. Book excerpt: Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.
Download or read book Apolipoprotein E and Alzheimer s Disease written by A.D. Roses and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 208 pages. Available in PDF, EPUB and Kindle. Book excerpt: There is now considerable genetic evidence that the type 4 allele of the apolipoprotein E gene is a major susceptibility factor associated with late-onset Alzheimer's disease, the common form of the disease defined as starting after sixty years of age. The role of apolipoprotein E in normal brain metabolism and in the pathogenesis of Alzheimer's disease are new and exciting avenues of research. This book, written by the most outstanding scientists in this new filed, is the first presentation of results concerning the implications of apolipoprotein E on the genetics, cell biology, neuropathology, biochemistry, and therapeutic management of Alzheimer's disease.
Download or read book Reviews on New Drug Targets in Age Related Disorders written by Paul C. Guest and published by Springer Nature. This book was released on 2021-03-16 with total page 274 pages. Available in PDF, EPUB and Kindle. Book excerpt: Aging is an inevitable part of life, and is becoming a worldwide social, economic and health problem due to the fact that an increasing proportion of individuals in the advanced age category have a higher probability of developing age-related disorders. New therapeutic approaches are still in need to decrease or slow the effects of such diseases in this aging society. Advances in ‘omic technologies such as genomics, transcriptomics, proteomics and metabolomics have significantly advanced our understanding of diseases in multiple medical areas. It is hoped that emerging hits from these analyses might be prioritized for further screening as potential novel drug targets for increasing the human healthspan in line with the lifespan, which will in turn lead to new therapeutic strategies and drug development projects by the pharmaceutical industry. This new book presents a series of reviews describing studies which have resulted in the identification of potential new drug targets for age-related disorders. Much of this information has come from ‘omic comparisons of healthy and disease states or from testing the effects of potential new therapeutic approaches. Each chapter will be presented in the context of specific chronic diseases or different therapeutic strategies, providing important information on disease mechanisms related to the aging process. This book will be of interest to researchers in the areas of aging and chronic disease, as well as clinical scientists, physicians, and major drug companies. With contributors from Australia, Brazil, Canada, France, Germany, India, Iran, Iraq, South Africa, South Korea, Thailand, Ukraine, United Kingdom, United States of America, Uruguay and Vietnam, this is a timely follow up to Guest’s previous book Reviews on New Drug Targets in Age-Related Disorders.
Download or read book Molecular Biology of Neurodegenerative Diseases Visions for the Future written by and published by Academic Press. This book was released on 2019-11-05 with total page 410 pages. Available in PDF, EPUB and Kindle. Book excerpt: Molecular Biology of Neurodegenerative Diseases: Visions for the Future, Volume 168 in the Progress in Molecular Biology and Translational Science series, provides the most topical, informative and exciting monographs available on a wide variety of research topics. The series includes in-depth knowledge on the molecular biological aspects of organismal physiology, with this release including chapters on Alzheimer's disease, Prion-like propagation of alpha-synuclein, What - if anything - can we learn about neurodegenerative diseases from yeast?, Mitochondrial rejuvenation and replacement as a novel strategy for treatment of age-related neurodegenerative diseases, Propagation and removal of cerebral amyloid angiopathy, and much more. - Includes comprehensive coverage of molecular biology - Presents ample use of tables, diagrams, schemata and color figures to enhance the reader's ability to rapidly grasp the information provided - Contains contributions from renowned experts in the field
Download or read book Animal Models of Cognitive Impairment written by Edward D. Levin and published by CRC Press. This book was released on 2006-06-22 with total page 395 pages. Available in PDF, EPUB and Kindle. Book excerpt: The costs associated with a drug's clinical trials are so significant that it has become necessary to validate both its safety and efficacy in animal models prior to the continued study of the drug in humans. Featuring contributions from distinguished researchers in the field of cognitive therapy research, Animal Models of Cognitive Impairmen
Download or read book Pathobiology of Alzheimer s Disease written by and published by Elsevier. This book was released on 1995-10-17 with total page 273 pages. Available in PDF, EPUB and Kindle. Book excerpt: Neuroscience Perspectives provides multidisciplinary reviews of topics in one of the most diverse and rapidly advancing fields in the life sciences.Whether you are a new recruit to neuroscience, or an established expert, look to this series for 'one-stop' sources of the historical, physiological, pharmacological, biochemical, molecular biological and therapeutic aspects of chosen research areas.The last decade has seen tremendous advances in our understanding of the pathobiology of Alzheimer's disease. These will lead to the first generation of drugs aimed at prevention rather than cure. This book covers some of the most important and exciting of these advances, with chapters written by many of the leading researchers in the field.With genetic studies as a backbone to this volume many chapters are devoted to the function and regulation of amyloid b-protein precursor (APP) and apolipoprotein E (ApoE). Other chapters describe cell biological approaches helping to piece together the link between the genetic alterations and the phenotype we call Alzheimer's disease.Although APP and its proteolytic cleavage product, amyloid b-protein, do not answer all the questions, detailed research into this system has undoubtedly increased our knowledge of the pathobiology of AD and has lead to the identification of other risk factors. Understanding the role of ApoE in the pathology of Alzheimer's disease promises to open a whole new field in AD research.* * Reviews the current knowledge of the pathogenesis of Alzheimer's Disease from a clinical perspective to a genetic and cell biological perspective* A comprehensive description of the role of amyloid B-protein precursor in Alzheimer's disease.* Up-to-date research data* Clear illustrations complement the text
Download or read book Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders written by Adeboye Adejare and published by Academic Press. This book was released on 2016-09-20 with total page 310 pages. Available in PDF, EPUB and Kindle. Book excerpt: Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer's Disease examines the drug discovery process for neurodegenerative diseases by focusing specifically on Alzheimer's Disease and illustrating the paradigm necessary to ensure future research and treatment success. The book explores diagnosis, epidemiology, drug discovery strategies, current therapeutics, and much more to provide a holistic approach to the discovery, development, and treatment of Alzheimer's Disease. Through its coverage of the latest research in targeted drug design, preclinical studies, and mouse and rat models, the book is a must-have resource for all pharmaceutical scientists, pharmacologists, neuroscientists, and clinical researchers working in this area. It illustrates why these drugs tend to fail at the clinical stage, and examines Alzheimer's Disease within the overall context of improving the drug discovery process for the treatment of other neurodegenerative disorders. - Provides a compilation of chemical considerations required in drug discovery for the treatment of neurodegenerative disorders - Examines different classes of compounds currently being used in discovery and development stages - Explores in vitro and in vivo models with respect to their ability to translate these models to human conditions - Distills the most significant information across multiple areas of Alzheimer's disease research to provide a single, comprehensive, and balanced resource
Download or read book Natural Products and Neuroprotection written by Cristina Angeloni and published by MDPI. This book was released on 2020-06-17 with total page 338 pages. Available in PDF, EPUB and Kindle. Book excerpt: Neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, and amyotrophic lateral sclerosis, are the most common pathologies of the central nervous system currently without a cure. They share common molecular and cellular characteristics, including protein misfolding, mitochondrial dysfunction, glutamate toxicity, dysregulation of calcium homeostasis, oxidative stress, inflammation, and ageing, which contribute to neuronal death. Efforts to treat these diseases are often limited by their multifactorial etiology. Natural products, thanks to their multitarget activities, are considered promising alternatives for the treatment of neurodegeneration. This book deals with two different forms of natural products: extracts and isolated compounds. The study of the bioactivity of the extracts is extremely important as many studies have demonstrated the synergistic effect of the combination of different natural products. On the other hand, the investigation of the activity of specifically isolated natural products can be also important to understand their cellular and molecular mechanisms and to define the specific bioactive components in extracts or foods. This book can be considered an important contribution to knowledge of the neuroprotective effect of natural products and presents a great deal of information, related to both the benefits but also the limitations of their use in counteracting neurodegeneration.
Download or read book Alzheimer s Disease written by Thimmaiah Govindaraju and published by Royal Society of Chemistry. This book was released on 2022-01-04 with total page 531 pages. Available in PDF, EPUB and Kindle. Book excerpt: Alzheimer’s disease is an increasingly common form of dementia and despite rising interest in discovery of novel treatments and investigation into aetiology, there are no currently approved treatments that directly tackle the causes of the condition. Due to its multifactorial pathogenesis, current treatments are directed against symptoms and even precise diagnosis remains difficult as the majority of cases are diagnosed symptomatically and usually confirmed only by autopsy. Alzheimer’s Disease: Recent Findings in Pathophysiology, Diagnostic and Therapeutic Modalities provides a comprehensive overview from aetiology and neurochemistry to diagnosis, evaluation and management of Alzheimer's disease, and latest therapeutic approaches. Intended to provide an introduction to all aspects of the disease and latest developments, this book is ideal for students, postgraduates and researchers in neurochemistry, neurological drug discovery and Alzheimer’s disease.
Download or read book Reducing the Impact of Dementia in America written by National Academies of Sciences Engineering and Medicine and published by . This book was released on 2022-04-26 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: As the largest generation in U.S. history - the population born in the two decades immediately following World War II - enters the age of risk for cognitive impairment, growing numbers of people will experience dementia (including Alzheimer's disease and related dementias). By one estimate, nearly 14 million people in the United States will be living with dementia by 2060. Like other hardships, the experience of living with dementia can bring unexpected moments of intimacy, growth, and compassion, but these diseases also affect people's capacity to work and carry out other activities and alter their relationships with loved ones, friends, and coworkers. Those who live with and care for individuals experiencing these diseases face challenges that include physical and emotional stress, difficult changes and losses in their relationships with life partners, loss of income, and interrupted connections to other activities and friends. From a societal perspective, these diseases place substantial demands on communities and on the institutions and government entities that support people living with dementia and their families, including the health care system, the providers of direct care, and others. Nevertheless, research in the social and behavioral sciences points to possibilities for preventing or slowing the development of dementia and for substantially reducing its social and economic impacts. At the request of the National Institute on Aging of the U.S. Department of Health and Human Services, Reducing the Impact of Dementia in America assesses the contributions of research in the social and behavioral sciences and identifies a research agenda for the coming decade. This report offers a blueprint for the next decade of behavioral and social science research to reduce the negative impact of dementia for America's diverse population. Reducing the Impact of Dementia in America calls for research that addresses the causes and solutions for disparities in both developing dementia and receiving adequate treatment and support. It calls for research that sets goals meaningful not just for scientists but for people living with dementia and those who support them as well. By 2030, an estimated 8.5 million Americans will have Alzheimer's disease and many more will have other forms of dementia. Through identifying priorities social and behavioral science research and recommending ways in which they can be pursued in a coordinated fashion, Reducing the Impact of Dementia in America will help produce research that improves the lives of all those affected by dementia.
